Does Rallies show 13F holders for MDGL?

Yes. Rallies tracks hedge fund and 13F ownership data for MDGL, including fund names, share counts, latest tracked quarter, and position changes when available.

Is MDGL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MDGL. It does not provide personalized investment advice.

MDGL (Madrigal Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) is a publicly traded Healthcare sector company. As of May 21, 2026, MDGL trades at $513.47 with a market cap of $12.04B and a P/E ratio of -39.89. MDGL moved +0.31% today. Year to date, MDGL is -12.73%; over the trailing twelve months it is +75.39%. Its 52-week range spans $200.63 to $615.00. Analyst consensus is strong buy with an average price target of $674.25. Rallies surfaces MDGL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns MDGL stock?

Hedge funds tracked by Rallies that own MDGL include Rokos Capital, Pentwater Capital, Bridgewater Associates, Farallon Capital, and Eisler Capital. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Madrigal Pharmaceuticals, Inc. Common Stock.

MDGL Key Metrics

Key financial metrics for MDGL
Metric	Value
Price	$513.47
Market Cap	$12.04B
P/E Ratio	-39.89
EPS	$-12.85
Dividend Yield	0.00%
52-Week High	$615.00
52-Week Low	$200.63
Volume	0
Avg Volume	0
Revenue (TTM)	$958.40M
Net Income	$-288.28M
Gross Margin	0.00%

Top Hedge Funds Holding MDGL

Rokos Capital holds 23.65K shares of MDGL, changed -68.69% as of Jun 30, 2024.
Pentwater Capital holds 4.00K shares of MDGL, changed +0.00% as of Mar 31, 2024.
Bridgewater Associates holds 3.92K shares of MDGL, changed -79.60% as of Mar 31, 2026.
Farallon Capital holds 3.32K shares of MDGL, changed +0.00% as of Mar 31, 2026.
Eisler Capital holds 2.88K shares of MDGL, changed +0.00% as of Jun 30, 2024.

Latest MDGL News

Madrigal jumps as Q1 revenue hits $311M on strong Rezdiffra uptake — May 6, 2026
Madrigal (MDGL) slides ahead of May 6 Q1 earnings, traders de-risk — May 5, 2026
Madrigal Secures ARO-PNPLA3 siRNA License with $25M Upfront, 46% Fat Reduction Data — May 5, 2026
Madrigal slides 3% as traders fade recent strength amid Rezdiffra margin focus — Apr 7, 2026
MDGL ticks higher as Rezdiffra sales momentum and 2026 outlook stay in focus — Apr 2, 2026

Recent MDGL Insider Trades

Soergel David sold 844 (~$435.42K) on May 18, 2026.
Dier Mardi sold 646 (~$279.03K) on Mar 6, 2026.
Dier Mardi sold 40 (~$17.00K) on Mar 6, 2026.

MDGL Analyst Consensus

8 analysts cover MDGL: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $674.25.

Common questions about MDGL

Who owns MDGL stock?: Hedge funds tracked by Rallies that own MDGL include Rokos Capital, Pentwater Capital, Bridgewater Associates, Farallon Capital, and Eisler Capital. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Madrigal Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for MDGL?: Yes. Rallies tracks hedge fund and 13F ownership data for MDGL, including fund names, share counts, latest tracked quarter, and position changes when available.
Is MDGL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MDGL. It does not provide personalized investment advice.